Novo Nordisk
novonordisk.lv
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Offices
Financials
Overview
Novo Nordisk ir starptautisks veselības aprūpes uzņēmums, kas dibināts 1923. gadā, kura galvenā mītne atrodas Dānijā pie Kopenhāgenas. Mūsu mērķis ir veicināt pārmaiņas cīņā ar cukura diabētu un citām smagām hroniskām slimībām – tādām kā aptaukošanās un retas asinis un endokrīnās slimības.
News
Novo Nordisk A/S (NVO) Stock: Drops as Semaglutide Helps 40% of Children Exit Obesity Classification
Novo Nordisk's STEP Young trial found semaglutide helped 40.4% of children exit obesity classification, while NVO stock closed 1.92% lower after the update.
Read more
Report
Novo Nordisk (NVO) Stock Dips Despite Promising Childhood Obesity Trial Results
Novo Nordisk (NVO) stock dropped 1.92% after ending two heart drug trials, though semaglutide showed 40% of children aged 6-12 reversed obesity in trials.
Read more
Report
Novo Nordisk stops 2 more trials for its heart disease medicine in fresh setback
Earlier this year, Novo said ziltivekimab failed to reduce the risk of heart attacks and strokes, diminishing expectations for other ongoing studies.
Read more
Report
Novo Nordisk stops two cardiovascular trials of drug aimed at lowering inflammation
The studies of a drug called ziltivekimab were aimed at taming inflammation as a way to improve cardiovascular health.
Read more
Report
Novo Nordisk's IL-6 drug flunks two more heart trials
Novo Nordisk has opted to discontinue two late-stage trials of IL-6 inhibitor ziltivekimab in heart failure, after taking an interim look at the data.
Read more
Report
Pro access
Upgrade to see all 33 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.